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Abstract

Background: Since the late 1980s sales and prescribing of newer antidepressants have increased dramatically in most European countries. We will use usage development in Denmark as an example. (Rose, MN). However the prevalence of depression is expected to be rather constant.

Objective: The primary aim is to analyse possible explanations factors that could add knowledge about the increased usage of antidepressants. 

Methods: We will describe the development in usage of newer antidepressants in the European countries in the light of the socio-economic societal development with the ideal of self-realisation and emphasising individual characteristics as flexibility, mobility, innovation, enterprise, willingness to change and adaption and vigourousness. The period we focus on is from 1988 and up to today, which correspond to the period characterised by increase of antidepressants. 

The societal development in this period also encompass change in the way the depression diagnose is made, with respect to the criteria for the disease but also the development of diagnostic tools. The pharmaceutical industry have improved their marketing of the products and through disease aware campaigns a special picture of the disease and its treatment is communicated throughout society.

Further we will through three different sociological explanations, identify the explanations with the strongest explanation sturdiness.

First the concept of medicalisation. Throughout many years there has been a discussion on how powerfull groups in society such as the government, the industri, the professsionals and many other groups are influenzing the citizens and make them use drugs much more than needed. The article will redefine this concept to a more narrow definition used in this paper.

Second the biopolitical concept focusing on the modern medical science, molequalar biopolitics, the experts in social life and the capitalization of life itself.

Third the concept of governmentality in modern societies, how relationship between government and citizens, as well as health professionals and patients are changed throughout new theories of power.














Over the last approximately 20 years there has been an increase in the use of antidepressants. The newer antidepressants, specific serotonin reuptake inhibitors, were introduced on the market in the late 1980s in the European countries and later on also other specific reuptake inhibitors were introduced. OECD has shown an increasing usage of antidepressants in all the OECD countries over a period of 2 years. The overall increase in usage of antidepressants in all OECD countries together is 40% from 2000 to 2005. Rose has shown the same development in the European countries expressed as a doubling in prescriptions of antidepressants over a 10 years period from 1990 to 2000 and a 14fold increase in prescriptions of the newer antidepressants of the type specific serotonin reuptake inhibitors. Nielsen and Gøtzsche have shown the same development in Denmark over a 30 years period, with a rather stable usage of other psychotropics but newer antidepressants and the group of benzodiazepines, which are used as anxiolytics or hynotics. 


Nielsen and Gøtzsche

We will use a modified model, which is based on a model proposed by Ronald Andersen for exploring the causes for the utilization of health care services, in this case utilization of antidepressants. (reference 4 Ronald Andersen). The model could encompass possible factors, which influence utilization of antidepressants, even if it was developed as a more general model for explanation of utilization of health care services. There is an upper level in the model, encompassing the social and political environment, for example the societal health perception,  health politics and legislation. There is a supply level encompassing general practitioners and psychiatrists, prescribing antidepressants and the pharmaceutical industry (5). On this level the working environment, professional attitudes towards health, illness and treatments, professional guidelines could influence the prescribing pattern. There is also a demand level, which is the population and the single person with subjective and objective needs. Income, health insurance status, personal values concerning health and illness, knowledge about disease and treatment and attitude toward health service could be some of the factors on this level that could influence utilization. All these are factors that could influence the utilization of drugs and antidepressants.


























Social- and political environment level.

In the 1960s there was on the one hand the movement of the anti-psychiatry and on the other hand the psychoanalytic dominance in psychiatry. But within a few decades the perception of the brains function changed to the idea of chemically communication between neurones and that the activity could influence behaviour. This grounded the biological psychiatry and cleared the way for the pharmaceutical industry researching in and developing treatment possibilities for depression. This added new theories and the receptors came into focus, being able to recognize certain amines and were either activated or blocked by the newer antidepressants. In this image neurotransmitters and receptors were imagined as locks and keys. It gave rise to the picture of smart drugs that could specifically lock into identified receptors being specific in their target and with a low adverse effect profile (2). Serotonin was believed to be the neurotransmitter linked to depression. Research, however, has never been able to support this theory, but it is still widely accepted (5). 

The prevalence of depression has been assessed by several sources to be around 5 – 10 % (reference 4) but also numbers up to 20% have been proposed. It should be supposed that the prevalence of depression would more or less constant, but the changing prescription patterns show that something is going on. In a period of 25 years the main indication for prescribing psychotropic drugs was anxiety, but this indication decreased as prescribing of antidepressants increased and prescribing of benzodiazepines decreased. It could be that depression is more common than previously recognized and that effective drugs, with more acceptable adverse effect profile, makes more people want to be treated for their depression. WHO published a report in 20001 claiming that depression affects more than 340 million people worldwide and gave the prediction that:
	“By the year 2020, if current trends for demographic and epidemiological 
	transition continue, the burden of depression will increase to 5.7% of the total
	burden of desease, becoming the second leading cause  of DALYs (disability
	adjusted life years) lost. Worldwide it will be second only to ischemic heart 
	disease for DALYs lost for both sexes. In the developed regions, depression
	will then be the highest ranking cause of burden of disease.” (14 World Health 
	Report 2001).
This has been questionned by the psychiatris and historian David Healy:”Nobody seemed to question how a society could have become so depressed so fast. Depression was now being touted as a serious illness; but the emergence of a comparable epidemic of any other serious illness on this scale would have led to serious questioning as to what had happened. There appeared to be no such questioning in the case of depression.” (howard brody hooked rowman and littlefield 2007).


In 1987, just before the SSRIs are being marketed the Diagnostic and Statistical Manual of mental diseases (DSM) was revised and published and carried on the major changes that were already started in the third edition of the manual. The DSM forms the background for researsch in psychiatric diseases and further was also in the beginning of the 1990s harmonised with the International Classification of Diseases (ICD 10) and form the basis for diagnosing psychiatric diseases. As a new approach to mental illness, symptoms, rather than speculations about cause-effect mechanisms, were described as the means to substantiate the diagnosis, and this change has had a major influence on the thinking about psychiatric diagnoses. New disorders were included and existing disorders were "exploded", e.g. anxiety neurosis was split into seven new disorders: agoraphobia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, simple phobia and social phobia (6). The symptom-based approach has been criticized for creating diseases, and normal life distress and sadness can today be classified as mental disease and thus be treated with drugs (7). It has been criticized that the criteria for major depressive disorder, as described in DSM IV and in ICD 10, have been changed in a direction where more and more normal life conditions could be picked up as major depression (8). The symptoms described as criteria for depression are now broad and common, for example fatigue, insomnia or diminished ability to concentrate, and do not distinguish between a disorder and expected reactions to a situational context, for example the loss of a beloved person. 

Many of the European national health authorities screening for depression is now recommended (2,3). The recommendation of screening finds support in WHO (5) and in several national guidelines, for example the NICE guidelines from the UK (2) and the recommendation from the US Preventive Services Task Force (3). From the WHO report “Mastering depression in primary care”(5) it appears that screening for well-being should be a standard procedure, in the same manner as screening for hypertension and that the WHO-5 well-being index could be used for screening all people for depression or reduced quality of life. This is though a recommendation, which goes beyond the available evidence. As it is recognised that there is problems with the evidence for general screening of the whole population the recommendation is screening in primary care of several subgroups that should be in high risk of depression. It is expected that screening will encompass approximately one million persons in Denmark.

The rationale behind this recommendation is that depressive disorders are a major health problem and that many disorders remain undetected. But there is also a current discussion about over- and under-treatment of depression and the risk of over-diagnosing depression (4).

However the recommendation of screening of risk groups for depression builds upon low evidence. It appears from the Danish guideline (1) that the evidence is on level IIa, corresponding to non randomised controlled studies. In the NICE guidelines (2) the recommendation of screening of high-risk groups is built on the evidence level C, corresponding to IV, which is expert committee reports or opinions or clinical experiences of respected authorities. In the U.S. preventive Task Force report (3) screening of the population is a B recoomendation, which means that there should at least be fair evidence that the service improves important health outcomes and concluded that benefits outweigh harms. Fair evidence is classified as evidence, which is sufficient to determine the effects on health outcome, but that the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes limits the strength of the evidence (6). It is though not understandable how it can be concluded that benefits outweigh harms, when the U.S. Task Force describe the potential harms of screening and treatment:” The potential harms of screening include false positive screening results, the inconvenience of further diagnostic work-up, the adverse effects and costs of treatment for patients who are incorrectly identified as being depressed, and potential adverse effects of labeling. None of the research reviewed provided useful empirical data regarding these potential adverse effects” (3).

A Cochrane review showed minimum of impact of screening on the detection of depression, however some smaller studies using a two stage selective procedure, whereby only patients scoring above a certain threshold were entered into the trials, suggested some effect. There was no evidence of clinical effect on the outcome of the depression (7). So there are conflicting opinions on systematic screening on population level but there seems to be a “general agreement” (1) that screening of high-risk groups is recommendable. However, relatively little is known of the impact of screening, particularly in primary care, on outcomes for those identified.

The prices of the drugs could influence the usage of them. Most of the EU countries use some kind of price control trying to reduce the pharmaceutical expenditure, which could include reference pricing, delay in approval, procedures and restrictions on dispending and prescribing, price freezing,  and reimbursement systems. As price control differ between EU countries, parallel trade with intermediaries buying pharmaceutical products in countries with lower prices and sell them in countries with higher prices. This could result in different prices on the antidepressants in different countries, influencing the utilisation in the different countries (reference).

Supply level

The pharmaceutical industry has researched and offered new treatments for depression. The SSRIs were approved for treatment of depression, but slowly other indications were also approved. Today at least 8 different indications are approved, and in some countries probably more. Some of these indications are:
	Major depression
	Bulimina nervosa
	Obsessive-compulsive condition
	Socialphobia
	Generalized anxiety
	Panic disorder
	Prevention of periodic episodes
	Post traumatic stress.
This was a extension of the indications, that also cleared the way for increased prescriptions and usage. Compared to earlier antidepressants; for example the tricyclic antidepressants, the newer antidepressants also had fewer and less serious adverse effects and together with a claimed better effect this could be used in the marketing of the newer antidepressants. 

In Europe there is a ban on direct to consumers advertisement, so the pharmaceutical industry has been forced to communicate their messages in other ways. This has among other expressed itself in disease awareness campaigns. One was run in UK and was called Defeat Depression campaign launched in 1992 by the Royal College of Psychiatrists in association with the Royal College of General Practitioners. The campaign was economically supported by one of the manufacturers of SSRIs (Reference Charles Medawar Social Audit ) http://www.socialaudit.org.uk/5103.htm (​http:​/​​/​www.socialaudit.org.uk​/​5103.htm​) and Davis Healy in let them eat Prozac Publisher: James Lorimer and. Company. 2003. The campaigns built on a two-fold strategy. First to alert physicians and others of the econimic burdens of untreated depression and the magnitude of the problem and second to educate the general practitioners to detect and treat depression.

A campaign of the same kind was seen in Denmark. It was run by the Psychiatry Association (both professionals and patients) and was also supported by the pharmaceutical industry. It reached the public through a disease awareness campaign in the television and reached the general practitioners through their own journal with an advertisement of the drug, another advertisement about a educational video they could get for free about how to detect depression in their patients and a third advertisement referring to the general disease awareness campaign that was also run in the television. 

In Denmark the general practitioners are mainly responsible for the large sales of psychoactive drugs, as 80-90% of all drugs are prescribed by them (42), and as the vast majority of patients treated for a mental, non-psychotic condition are treated in general practice (43). Unfortunately, general practitioners rely on the drug industry as their main information source (45-47), and most doctors believe that the information is helpful for them, although it is rather clear that this interaction has negative consequences for the patients (27). Not all countries in the EU though have a health system build on general practitioners as gate keepers to the rest of the health system, but from the consumption figures it seems as if the development in increased consumption still happens.

Demand level

There is evidence that factors as poor housing, poverty, unemployment or stressful working conditions are associated with increased levels of psychiatric morbidity. But this seems insufficient to account for the rapid increase in diagnose and prescription of antidepressants. Earlier sociological explanations of increase in mental disorders was for example that urban life stressed the individual leading to what was called neurasthenia or that capitalism isolates the individual, or that patriarchry withheld women from rights and equality. But also these explanations seem insufficient to account for the rapid increase. (Rose).

The society in many of the European countries, if not all, have moved into a direction of individualized societies. There are no longer traditions that dertermin our lives, it is up to every single person to decide. This leaves the individual to orientate in all posibilies given in the modern society and to decide how to create a happy and successful life. So at the one hand the individual can choose between all possibilities, and on the other hand the society also build a framework, which also give limitations. The happy and successful life is understood as a life in high tempo and with room for everything. This puts a lot of people in a dilemma and some will fail in their life, as it is up to the individual to create the successful life. Stress and depression are a reaction to this (13 Anthony Giddens reference). Ehrenberg has also suggested that depression is the backside of the new individualidity. So if the individual is unable to live up to the individual responsibility, personal initiative and active self-fulfilment the risk is depression.

As mentioned above the pharmaceutical companies have an indirect influence on the construction and definition of diseases, through people involved in DSM with ties to the industry (10). Further the pharmaceutical companies have invested ressources in raising public awareness about underdiagnosed and undertreated problems, like for example depression. This have been executed in coalition with other stakeholders like doctors and patientsgroups (10). The key strategy is to target news media with stories about the disease, creating fear and worries and to draw attention to the very latest treatment. A part of the campaigns is also to widen up the boundaries for when a condition or distress should be treated or when treatment is possible. Disease awareness campaigns almost alllways propose the reader or wiever to seek the doctor if any of the mentioned symptoms are present. So in one movement the consumer is made aware of a distress or a condition which is anoying in daily life, is aware of a possible treatment (and the company behind) and is on the way to the doctor (11). 
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